Understanding and managing the impact of the Covid-19 pandemic and lockdown on patients with multiple sclerosis

References

• Tsivgoulis G, Palaiodimou L, Katsanos AH, et al. Neurological manifestations and implications of COVID-19 pandemic. Ther Adv Neurol Disord. 2020;13:1–14.
   Web of Science ®Google Scholar
• Rae-Grant A, Day GS, Marrie RA, et al. Practice guideline recommendations summary: disease-modifying therapies for adults with multiple sclerosis: report of the guideline development, dissemination, and implementation Subcommittee of the American Academy of Neurology. Neurology. 2018;90:777–788.
   PubMed Web of Science ®Google Scholar
• Sastre-Garriga J, Tintore M, Montalban X. Keeping standards of multiple sclerosis care through the COVID-19 pandemic. MultScler. 2020;26:1153–1156.
   Google Scholar
• Portaccio E, Fonderico M, Hemmer B, et al. Impact of COVID-19 on multiple sclerosis care and management: results from the European committee for treatment and research in multiple sclerosis survey. MultScler. 2021;25:13524585211005339.
   Google Scholar
• Mateen FJ, Rezaei S, Alakel N, et al. Impact of COVID-19 on U.S. and Canadian neurologists’ therapeutic approach to multiple sclerosis: a survey of knowledge, attitudes, and practices. J Neurol. 2020;267:3467–3475.
   PubMed Web of Science ®Google Scholar
• Moccia M, Lanzillo R, Brescia Morra V, et al. Assessing disability and relapses in multiple sclerosis on tele-neurology. Neurol Sci. 2020;41:1369–1371.
   PubMed Web of Science ®Google Scholar
• Di Tella S, Pagliari C, Blasi V, et al. Integrated telerehabilitation approach in multiple sclerosis: a systematic review and meta-analysis. J Telemed Telecare. 2020;26:385–399.
   PubMed Web of Science ®Google Scholar
• Kang L, Li Y, Hu S, et al. The mental health of medical workers in Wuhan, China dealing with the 2019 novel coronavirus. Lancet Psychiatry. 2020;7:E14.
   PubMed Web of Science ®Google Scholar
• Mowbray H. In Beijing, coronavirus 2019‐nCoV has created a siege mentality. BMJ. 2020;368:m516.
   PubMed Web of Science ®Google Scholar
• Motolese F, Rossi M, Albergo G, et al. The psychological Impact of COVID-19 pandemic on people with multiple sclerosis. Front Neurol. 2020;11:580507.
   PubMed Web of Science ®Google Scholar
• Alschuler KN, Roberts MK, Herring TE, et al. Distress and risk perception in people living with multiple sclerosis during the early phase of the COVID-19 pandemic. MultSclerRelatDisord. 2021;47:102618.
   Google Scholar
• Costabile T, Carotenuto A, Lavorgna L, et al. COVID-19 pandemic and mental distress in multiple sclerosis: implications for clinical management. Eur J Neurol. 2020. DOI:10.1111/ene.14580
   PubMed Web of Science ®Google Scholar
• Bonavita S, Sparaco M, Russo A, et al. Perceived stress and social support in a large population of people with multiple sclerosis recruited online through the COVID-19 pandemic. Eur J Neurol. 2020.
   Web of Science ®Google Scholar
• Boeschoten RE, Braamse AMJ, Beekman ATF, et al. Prevalence of depression and anxiety in multiple sclerosis: a systematic review and meta‐analysis. J Neurol Sci. 2017;372:331‐41.
   PubMed Web of Science ®Google Scholar
• Zhang Y, Staker E, Cutter G, et al. Perceptions of risk and adherence to care in MS patients during the COVID-19 pandemic: a cross-sectional study. MultSclerRelatDisord. 2021;50:102856.
   Google Scholar
• Chiaravalloti ND, Amato MP, Brichetto G, et al. The emotional impact of the COVID-19 pandemic on individuals with progressive multiple sclerosis. J Neurol. 2021;268:1598–1607.
   PubMed Web of Science ®Google Scholar
• Charcot JM. Lectures on the diseases of the nervous system: delivered at la Salpêtrière. Lea. London: The New Sydenham Society; 1879. [cited 2020 Apr 26]. Available from: https://archive.org/details/lecturesondiseas02char
   Google Scholar
• Artemiadis AK, Anagnostouli MC, Alexopoulos EC. Stress as a risk factor for multiple sclerosis onset or relapse: a systematic review. Neuroepidemiology. 2011;36:109–120.
   PubMed Web of Science ®Google Scholar
• Mohr DC, Goodkin DE, Bacchetti P, et al. Psychological stress and the subsequent appearance of new brain MRI lesions in MS. Neurology. 2000;55:55–61.
   PubMed Web of Science ®Google Scholar
• Mitsonis CI, Zervas IM, Mitropoulos PA, et al. The impact of stressful life events on risk of relapse in women with multiple sclerosis: a prospective study. Eur Psychiatry. 2008;23:497–504.
   PubMed Web of Science ®Google Scholar
• Mohr DC, Lovera J, Brown T, et al. A randomized trial of stress management for the prevention of new brain lesions in MS. Neurology. 2012;79:412–419.
   PubMed Web of Science ®Google Scholar
• Burns MN, Nawacki E, Kwasny MJ, et al. Do positive or negative stressful events predict the development of new brain lesions in people with multiple sclerosis? Psychol Med. 2014;44:349–359.
   PubMed Web of Science ®Google Scholar
• Artemiadis AK, Vervainioti AA, Alexopoulos EC, et al. Stress management and multiple sclerosis: a randomized controlled trial. Arch Clin Neuropsychol. 2012;27:406–416.
   PubMed Web of Science ®Google Scholar
• Mohr DC, Goodkin DE, Nelson S, et al. Moderating effects of coping on the relationship between stress and the development of new brain lesions in multiple sclerosis. Psychosom Med. 2002;64:803–809.
   PubMed Web of Science ®Google Scholar
• Carletto S, Tesio V, Borghi M, et al. The effectiveness of a body-affective mindfulness intervention for multiple sclerosis patients with depressive symptoms: a randomized controlled clinical trial. Front Psychol. 2017;30:2083.
   Google Scholar
• Cavanagh K, Churchard A, O’Hanlon P, et al. A randomised controlled trial of a brief online mindfulness-based intervention in a non-clinical population: replication and extension. Mindfulness (N Y). 2018;9:1191–1205.
   PubMed Web of Science ®Google Scholar
• Carotenuto A, Scandurra C, Costabile T, et al. Physical exercise moderates the effects of disability on depression in people with multiple sclerosis during the COVID-19 outbreak. J Clin Med. 2021;10:1234.
   PubMed Web of Science ®Google Scholar
• Cutler D. How will COVID-19 affect the health care economy? JAMA Health Forum. 2020;1:e200419.
   Google Scholar
• Amor S, Baker D, Khoury SJ, et al. SARS-CoV-2 and multiple sclerosis: not all immune depleting DMTs are equal or bad. Ann Neurol. 2020;87:794–797.
   PubMed Web of Science ®Google Scholar
• Burkill S, Montgomery S, Hajiebrahimi MH, et al. Mortality trends for multiple sclerosis patients in Sweden from 1968 to 2012. Neurology. 2017;89:555–562.
   PubMed Web of Science ®Google Scholar
• Sormani MP. An Italian programme for COVID-19 infection in multiple sclerosis. Lancet Neurol. 2020;19:481–482.
   PubMed Web of Science ®Google Scholar
• Peeters LM, Parciak T, Walton C, et al. COVID-19 in people with multiple sclerosis: a global data sharing initiative. MultScler. 2020;26:1157–1162.
   Google Scholar
• Parrotta E, Kister I, Charvet L, et al. COVID-19 outcomes in MS: observational study of early experience from NYU multiple sclerosis comprehensive care center. Neurol Neuroimmunol Neuroinflamm. 2020;7:e835.
   PubMed Web of Science ®Google Scholar
• Zhou F, Yu T, Du R, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020;395:1054–1062.
   PubMed Web of Science ®Google Scholar
• Sepúlveda M, Llufriu S, Martínez-Hernández E, et al. Incidence and Impact of COVID-19 in MS: a survey from a Barcelona MS unit. Neurol Neuroimmunol Neuroinflamm. 2021;8:e954.
   PubMed Web of Science ®Google Scholar
• Louapre C, Collongues N, Stankoff B, et al. Clinical characteristics and outcomes in patients with coronavirus disease 2019 and multiple sclerosis. JAMA Neurol. 2020;77:1079–1088.
   PubMed Web of Science ®Google Scholar
• Salter A, Fox RJ, Newsome SD, et al. Outcomes and risk factors associated with SARS-CoV-2 infection in a North American registry of patients with multiple sclerosis. JAMA Neurol. 2021;78: 699–08.
   PubMed Web of Science ®Google Scholar
• Sormani MP, De Rossi N, Schiavetti I, et al. Disease-modifying therapies and coronavirus disease 2019 severity in multiple sclerosis. Ann Neurol. 2021;89:780–789.
   PubMed Web of Science ®Google Scholar
• Fernandes PM, O’Neill M, Kearns PKA, et al. Impact of the first COVID-19 pandemic wave on the Scottish multiple sclerosis register population. Wellcome Open Res. 2020;5:276.
   PubMedGoogle Scholar
• Correale J, Fiol M, Gilmore W. The risk of relapses in multiple sclerosis during systemic infections. Neurology. 2006;67:652–659.
   PubMed Web of Science ®Google Scholar
• Marrodan M, Alessandro L, Farez MF, et al. The role of infections in multiple sclerosis. MultScler. 2019;25:891–901.
   Google Scholar
• Etemadifar M, Sedaghat N, Aghababaee A, et al. COVID-19 and the risk of relapse in multiple sclerosis patients: a fight with no bystander effect? MultSclerRelatDisord. 2021;51:102915.
   Google Scholar
• Ghajarzadeh M, Bonavita S. Are patients with multiple sclerosis (MS) at higher risk of COVID-19 infection? Neurol Sci. 2020;41:2315–2316.
   PubMed Web of Science ®Google Scholar
• Al-Ani M, Elemam NM, Hundt JE, et al. Drugs for multiple sclerosis activate natural killer cells: do they protect against COVID-19 infection? Infect Drug Resist. 2020;13:3243–3254.
   PubMed Web of Science ®Google Scholar
• Ciotti JR, Grebenciucova E, Moss BP, et al. Multiple sclerosis disease-modifying therapies in the COVID-19 era. AnnNeurol. 2020;88:1062–1064.
   Web of Science ®Google Scholar
• Bastard P, Rosen LB, Zhang Q, et al. Autoantibodies against type I IFNs in patients with life‐threatening Covid‐19. Science. 2020;370:eebd4585.
   Web of Science ®Google Scholar
• Zhang Q, Bastard P, Liu Z, et al. Inborn errors of type I IFN immunity in patients with life‐threatening Covid‐19. Science. 2020;370:eebd4570.
   Web of Science ®Google Scholar
• Blanco‐Melo D, Nilsson‐Payant BE, Liu WC, et al. Imbalanced host response to SARS‐CoV‐2 drives development of COVID‐19. Cell. 2020;181:1036–45.e9.
   PubMed Web of Science ®Google Scholar
• Reder AT, Centonze D, Naylor ML, et al. COVID-19 in patients with multiple sclerosis: associations with disease-modifying therapies. CNS Drugs. 2021;35:317–330.
   PubMed Web of Science ®Google Scholar
• Chen X, Jensen PE. The role of B lymphocytes as antigen-presenting cells. Arch Immunol Ther Exp (Warsz). 2008;56:77–83.
   PubMed Web of Science ®Google Scholar
• Meca-Lallana V, Aguirre C, Río B, et al. COVID-19 in 7 multiple sclerosis patients in treatment with ANTI-CD20 therapies. MultSclerRelatDisord. 2020;44:102306.
   Google Scholar
• Giovannoni G, Hawkes C, Lechner-Scott J, et al. The COVID-19 pandemic and the use of MS disease modifying therapies. MultSclerRelatDisord. 2020;39:102073.
   Google Scholar
• Giovannoni G. Cladribine to treat relapsing forms of multiple sclerosis. Neurotherapeutics. 2017;14:874–887.
   PubMed Web of Science ®Google Scholar
• Dalla Costa G, Leocani L, Montalban X, et al. Real-time assessment of COVID-19 prevalence among multiple sclerosis patients: a multicenter European study. Neurol Sci. 2020;41:1647–1650.
   PubMed Web of Science ®Google Scholar
• Kloc M, Ghobrial RM. The multiple sclerosis (MS) drugs as a potential treatment of ARDS in COVID-19 patients. MultSclerRelatDisord. 2020;45:102437.
   Google Scholar
• Dhib-Jalbut S, Marks S. Interferon-beta mechanisms of action in multiple sclerosis. Neurology. 2010;74(Suppl 1):S17–24.
   PubMed Web of Science ®Google Scholar
• Sigrist CJ, Bridge A, Le Mercier P. A potential role for integrins in host cell entry by SARS-CoV-2. Antivir Res. 2020;177:104759.
   PubMed Web of Science ®Google Scholar
• Hauser SL, Bar-Or A, Comi G, et al. Ocrelizumab versus Interferon Beta-1a in relapsing multiple sclerosis. N Engl J Med. 2017;376:221–234.
   PubMed Web of Science ®Google Scholar
• Bar-Or A, Grove RA, Austin DJ, et al. Subcutaneous ofatumumab in patients with relapsing-remitting multiple sclerosis: the MIRROR study. Neurology. 2018;90:e1805–e14.
   PubMed Web of Science ®Google Scholar
• Wiendl H, Carraro M, Comi G, et al. Lymphocyte pharmacodynamics are not associated with autoimmunity or efficacy after alemtuzumab. Neurol Neuroimmunol Neuroinflamm. 2020;7:e536.
   Web of Science ®Google Scholar
• Gilli F, Li L, Royce DB, et al. Treatment of Theiler’s virus induced demyelinating disease with teriflunomide. J Neurovirol. 2017;23:825–838.
   PubMed Web of Science ®Google Scholar
• Olagnier D, Farahani E, Thyrsted J, et al. SARS-CoV2-mediated suppression of NRF2-signaling reveals potent antiviral and anti-inflammatory activity of 4-octyl-itaconate and dimethyl fumarate. Nat Commun. 2020;11:4938.
   PubMed Web of Science ®Google Scholar
• Thakolwiboon S, Zhao-Fleming H, Pan J, et al. Disease-modifying therapies during the COVID-19 outbreak: a narrative review of international and national recommendations. Int J MS Care. 2020;22:151–157.
   PubMedGoogle Scholar
• Multiple Sclerosis International Federation. The coronavirus and MS – global advice [Internet]. [Published 2020; Updated 2020 Mar 18; cited 2020 Apr 14]. Available from: https://www.msif.org/news/2020/02/10/the-coronavirus-and-ms-what-you-need-to-know/
   Google Scholar
• European multiple sclerosis platform coronavirus disease (COVID-19) and MS [Internet]. [ Published 2020; cited 2020 Apr 14]. Available from: http://www.emsp.org/news-messages/coronavirus-disease-covid-19-and-multiple-sclerosis/
   Google Scholar
• Achiron A, Mandel M, Dreyer-Alster S, et al. Humoral immune response to COVID-19 mRNA vaccine in patients with multiple sclerosis treated with high-efficacy disease-modifying therapies. Ther Adv Neurol Disord. 2021;14:17562864211012835. DOI: 10.1177/17562864211012835.
   Web of Science ®Google Scholar
• Ciotti JR, Valtcheva MV, Cross AH. Effects of MS disease-modifying therapies on responses to vaccinations: a review. MultSclerRelatDisord. 2020;45:102439.
   Google Scholar
• Olberg HK, Eide GE, Cox RJ, et al. Antibody response to seasonal influenza vaccination in patients with multiple sclerosis receiving immunomodulatory therapy. Eur J Neurol. 2018;25:527–534.
   PubMed Web of Science ®Google Scholar
• Von Hehn C, Howard J, Liu S, et al. Immune response to vaccines is maintained in patients treated with dimethyl fumarate. Neurol Neuroimmunol NeuroInflamm. 2018;5:e409.
   PubMed Web of Science ®Google Scholar
• Bar-Or A, Wiendl H, Miller B, et al. Randomized study of teriflunomide effects on immune responses to neoantigen and recall antigens. Neurol Neuroimmunol NeuroInflamm. 2015;2:e70.
   PubMed Web of Science ®Google Scholar
• Lberg HK, Cox RJ, Nostbakken JK, et al. Immunotherapies influence the influenza vaccination response in multiple sclerosis patients: an explorative study. MultScler. 2014;20:1074–1080.
   Google Scholar
• Metze C, Winkelmann A, Loebermann M, et al. Immunogenicity and predictors of response to a single dose trivalent seasonal influenza vaccine in multiple sclerosis patients receiving disease-modifying therapies. CNS Neurosci Ther. 2019;25:245–254.
   PubMed Web of Science ®Google Scholar
• Kappos L, Mehling M, Arroyo R, et al. Randomized trial of vaccination in fingolimod-treated patients with multiple sclerosis. Neurology. 2015;84:872–879.
   PubMed Web of Science ®Google Scholar
• Ufer M, Shakeri-Nejad K, Gardin A, et al. Impact of siponimod on vaccination response in a randomized, placebo-controlled study. Neurol Neuroimmunol NeuroInflamm. 2017;4:e398.
   PubMed Web of Science ®Google Scholar
• National multiple sclerosis society [Internet]. [ Published 2021 Mar 22]. Available from: https://www.nationalmssociety.org/coronavirus-covid-19-information/multiple-sclerosis-and-coronavirus/covid-19-vaccine-guidance/Timing-MS-Medications-with-COVID-19-Vaccines
   Google Scholar
• Bar-Or A, Calkwood JC, Chognot C, et al. Effect of ocrelizumab on vaccine responses in patients with multiple sclerosis the VELOCE study. Neurology. 2020;95:e1999–e2008.
   PubMed Web of Science ®Google Scholar
• Zheng C, Kar I, Chen CK, et al. Multiple sclerosis disease‑modifying therapy and the COVID‑19 pandemic: implications on the risk of infection and future vaccination. CNS Drugs. 2020;34:879–896.
   PubMed Web of Science ®Google Scholar
• McCarthy CL, Tuohy O, Compston DAS, et al. Immune competence after alemtuzumab treatment of multiple sclerosis. Neurology. 2013;81:872–876.
   PubMed Web of Science ®Google Scholar
• Multiple sclerosis society [Internet]. [ Published 2021 May 11]. Available from: https://www.mssociety.org.uk/what-we-do/news/ms-society-medical-advisers-release-consensus-statement-covid-19-vaccines
   Google Scholar
• Polack FP, Thomas SJ, Kitchin N, et al. Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine. N Engl J Med. 2020;383:2603–2615.
   PubMed Web of Science ®Google Scholar
• Kivity S, Agmon-Levin N, Blank M, et al. Infections and autoimmunity: friends or foes? Trends Immunol. 2009;30:409–414.
   PubMed Web of Science ®Google Scholar
• Farez MF, Correale J. Yellow fever vaccination and increased relapse rate in travelers with multiple sclerosis. Arch Neurol. 2011;68:1267–1271.
   PubMedGoogle Scholar
• Mailand MT, Frederiksen JL. Vaccines and multiple sclerosis: a systematic review. J Neurol. 2017;264:1035–1050.
   PubMed Web of Science ®Google Scholar
• Achiron A, Dolev M, Menascu S, et al. COVID-19 vaccination in patients with multiple sclerosis: what we have learnt by February 2021. MultScler. 2021;27:864–870.
   Google Scholar